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ABSTRACT  Plasma cholesteryl ester transfer protein (CETP) facilitates neutral lipid 
exchange among lipoproteins. As in the case of naturally CETP –deficient animals such 
as mice, rat and dogs, the deficiency of CETP in human results in increased HDL levels 
due to decreased catabolism of HDL apoA-I and decreased LDL levels due to increased 
catabolism of LDL apoB. Also, post-prandial lipemia is diminished, and remnant 
cholesterol levels are also decreased. Genetic polymorphisms of the CETP gene 
promoter slightly decrease plasma CETP activity (-20%) and accordingly increase 
HDL-C concentration,.  Meta-analysis of clinical data has suggested that these changes 
result in decreased thereby decreasing coronary risk in meta-analyses. The Llipoprotein 
phenotype found in CETP-deficient heterozygotes, who had decreased plasma CETP 
activity by –40~50%, appeared to be anti-atherogenic in most studies. However, the 
effect on atherogenicity remains to be established in a large population study of subjects 
with very high HDL (>100 mg/dl) by due to homozygous CETP deficiency.  The result 
is not predictable, because large, apoE-rich HDL would might on the one hand operate 
as a platform of apoCs and apoE and lipoprotein-associated enzymes but on the other 
hand it is be less active cholesterol acceptors for ABCA1 transporters. 
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1. Introduction (Figure 1) 
Plasma LDL transports cholesterol from liver to peripheral tissues including adrenal 
glands and gonads. On the other hand, HDL transports cholesterol from peripheral 
tissues including atheroma to liver, subsequently to bile and feces via so-called reverse 
cholesterol transport (RCT) pathway. Cholesterol structure is resistant to enzymatic 
degradation in a humans body,.   only thethe only pathway to modify cholesterol is its 
hydroxylation for excretion from the body. 
      In human, HDL is consistsed of heterogenous particles heterogeneous in size, 
density and apolipoprotein composition. HDL is a vehicles for cholesterol, triglyceride, 
and phospholipids. Also, HDL has several apolipoproteins and enzymes on its surface 
that either promoteing or inhibiting triglyceride or phospholipids lipolysis, inhibiting 
hydroperoxidation of lipids, and promoteing lipid transfer among lipoproteins. In 
addition, HDL may be a platform for complement regulation, coagulation and 
inflammation [Scanu and Edelstein, 2008]. 
     Plasma HDL content islevels are usually measured as cholesterol levels 
concentration, but its particle numbers are better assessed by apolipoprotein A-I levels. 
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This distinction may be due in part to the fact that As inter-individual differences of 
plasma HDL-cholesterol, HDL2-cholesteol levels appeared to be highly variable, but 
HDL3 remains constant. Smoking, and male sex decreases HDL2 levels, but alcohol 
intake and exercise increase them. HDL2 levels were determined by result from 
catabolismc rate of apolipoprotein A-I and A-II rather than altered synthesistic rate. The 
catabolic rate of HDL apolipoproteins is determined by HDL particle size. The smaller 
HDL tends to be faster catabolized in the kidney or other tissues. One of the 
determinants of HDL neutral lipid composition is plasma cholesteryl ester transfer 
protein (CETP).  
  In incubated human plasma, transfer and equilibration of lecithin: cholesterol 
acyltransferase (LCAT)-generated CE is found, but the activity transferring CE among 
lipoproteins was not found in rat [Barter and Lally, 1978]. Similarly, mice, dog, and 
pig were members of a group of low plasma CETP activity, but rabbit and monkey 
belong to a group of high CETP activity. Human, hamster, guinea pig and chicken 
belong to a group of with intermediate CETP activity. Interestingly, more phospholipid 
transfer protein activity is found in plasmas of low CETP activity animals [Ha and 
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Barter 1982; Cheung et al. 1996].  
  Plasma CETP binds neutral lipids (CE or TG) and PL on HDL3, but CETP selectively 
promotes an exchange of CE and TG among lipoproteins. SinceOn the one hand 
HDL-TG couldcan be hydrolyzed by hepatic lipase, and on the other hand plasma CETP 
decreases HDL particle size via CE/TG exchange between chylomicron / VLDL and 
HDL. Thus CETP, thereby accelerates thing a catabolic rate of HDL apolipoproteins 
[Lamarche et al. 1999]. 
2. Structure of CETP 
Plasma CETP was initially isolated as a highly purified 74kD protein [Pattnaik et al. 
1978]. The human CETP gene is located at chromosome 16q13, near the locus of LCAT 
gene. The CETP gene consists of 16 exons, spanning 25kb [Agellon et al. 1991]. The 
CETP mRNA encodes 476 amino acids [Drayna et al. 1987]. The mature CETP 
contains four N-linked sugars (88, 240, 341, and 396) with variable glycosylation site of 
341Asn [Stevenson et al. 1993]. CETP mRNA is expressed in various tissues, but liver 
cells, adipocytes and macrophages are abundant sources. Exon 9 works a cassette exon 
to generate short mRNA missing the sequences in frame in addition to full-length 
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mRNA, but the splice-out variant is not efficiently secreted [Inazu et al. 1992]. 
   The C-terminal 26 amino acids of CETP form an amphipathic helix. Hydrophic 
residues bind to surface lipoproteins, and hydrophobic residues such as Leu, Phe are 
essential for binding neutral lipids such as CE and TG [Wang et al. 1993]. 
   The crystal structure of CETP shows that CETP forms a long tunnel occupied by 
four lipid molecules, two of CE or TG located inside of the tunnel and two of PL 
plugging both sides of the tunnel openings. CETP is one of the lipopolysaccharide 
binding protein (LBP) family members. CETP exhibits an elongated boomerang shape 
located on the lipoprotein surface. Based on molecular size, CETP might prefer CE 
transfer rather than TG because of steric hindrance to TGs at the tunnel neck around 
residues of 433, 443, 457, and 459 [Qiu et al. 2007]. 
3. Regulation of CETP expression 
Cholesterol-rich and saturated fat-rich diet increased CETP expression via a liver X 
receptor (LXR) element in the promoter, a direct repeat of a nuclear receptor binding 
sequence separated by 4 nucleotides (DR4) [Luo and Tall. 2001]. 
   Among drugs that lower lipid levels, probucol increased plasma CETP activity 
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(+20%), but pravastatin decreased it (-20%) [Inazu et al. 1999]. Statins decrease both 
cholesterol and oxysterosl, the latter being a ligand for LXRα activity [Masson et al. 
2004]. Thus, statins could decrease CETP mRNA levels through diminished LXR 
activity. However, the molecular effect of probucol on CETP expression is unknown, 
but it may be associated with increased cholesterol content in the liver by the remnant 
pathway. Unlike bezafibrate, fenofibrate decreased plasma CETP activity (-20~30%) 
[Guerin et al. 1996; Watts et al. 2006]. Since a putative PPRE is located in the just 
upstream of the LXRαsite, PPARα could suppress CETP promoter activity by 
antagonizing LXR activity [Cheema et al. 2005].  
   Nicotinic acid is a well-established lipid-lowering agent. Side effects such as 
flushing may restrict drug usage, however, recent identification of a G protein-coupled 
receptor GPR109A and of a PGD2 receptor antagonist (laropiprant) may provide 
strategies to control side effects. Nicotinic acid is a powerful inhibitor of fat-mobilizing 
lipolysis via hormone-sensitive lipase in adipose tissue, and therefore limits FFA flux 
into the liver. Nicotinic acid lowers TG as well as Lp(a) levels, and increases HDL-C 
levels by ~20-40%. Nicotinic acid may induce PPARγ expression but it is also 
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reported to lower CETP activity. Nicotinic acid increased HDL cholesterol levels by 
reducing hepatic CETP mRNA only in mice expressing the human CETP transgene 
[Hernandez et al. 2007; Van der Hoorn et al. 2008].   
4. Function of CETP 
LCAT promotes FC esterification in HDL3 and CETP transfers newly-esterified CE 
from HDL3 to VLDL or chylomicrons. Thus, these tandem reactions appeared to be 
physiological. However, it has been unclear whether or not CETP is pro-atherogenic, 
but it is likely that its atherogenicity is dependent on the metabolic context of 
lipoprotein receptors expressed in the liver, which are major determinants of RCT 
pathways to the liver. 
4.1 LCAT, cholesterol esterification, and CE transfer rate (Table 1) 
  Table 1 shows simultaneously determined plasma exogenous LCAT activity and CER 
and exogenous CETP activity in young women. Plasma cholesterol esterification rate 
(CER) is an endogenous LCAT reaction, which shows only ~20% of maximal 
enzymatic activity of LCAT. Net CE transfer rate from HDL to VLDL is only 20~50 
nmol/ml/h despite exogenous CETP activity ~200 nmol/ml/h [Pruneta et al. 1999]. 
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Since net CE transfer rate is smaller than that of CER, CE in HDL needs to be directly 
catabolized in liver. Therefore plasma VLDL levels appear to be a rate-limiting step of 
net CE transfer rate in the fasting state. However, in the post-prandial state, net CE 
transfer is accelerated because the increased VLDL / chylomicrons provides increased 
CE acceptor capacity, and the clearance of LDL-CE or remnant-CE is dependent on 
LDL-receptor activity or remnant receptor (LRP) in the liver. Since HDL-FC is more 
rapidly catabolized in liver than HDL-CE in a monkey study, selective uptake of FC 
without endocytosis of HDL apolipoproteins appears to be a predominant pathway of 
HDL-C catabolism in the liver [Scobey et al. 1989]. Thus HDL-CE pathways play 
minor roles in human HDL-cholesterol catabolism [Schwartz et al. 2004]. Also, FC 
from HDL is efficiently secreted in bile, but not from other lipoproteins [Robins and 
Fasulo, 1997]. Thus, cholesterol esterification is not necessarily required for the 
selective uptake of HDL-cholesterol in the liver via hepatic lipase and SR-BI mediated 
RCT pathways. The lipoprotein phenotype of high HDL and the low CER appear to be 
anti-atherogenic because efficient RCT is maintained in the liver. 
4.2 Modulators of lipid transfer  
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CETP-mediated lipid transfer is not preferably directed toward a specific lipoprotein in 
a reconstituted system. Because CE is generated in HDL via the LCAT reaction, higher 
CE concentrations are found in HDL Therefore, net CE transfer operates from HDL to 
other lipoproteins in vivo. Similarly, because chylomicrons and VLDL are rich in TG, 
net TG transfer is found from chylomicron / VLDL to other lipoproteins via 
hetero-exchange of CE and TG. In addition, some specific apolipoproteins and TG 
lipolysis occurring during the post-prandial state would modify the direction of lipid 
transfer among lipoproteins. 
  As a modulator of CE transfer, apoF was identified as lipid transfer inhibitor protein 
(LTIP). LTIP inhibits CE transfer between VLDL and LDL, whereas it increases CE 
transfer from HDL to VLDL [Wang and Morton 1999]. PLTP promotes PL transfer 
from VLDL to HDL, in addition to the PL transfer activity of CETP. Also, PLTP 
possesses free cholesterol and vitamin E transfer activity. As CE acceptors of CE 
transfer reaction, VLDL and chylomicrons are active when lipolysis has occurred. 
VLDL-bound LPL and FFA levels may have a positive effect on the binding between 
CETP and lipoproteins, thereby accelerating CE mass transfer. 
 9/7/2017 Akihiro INAZU  
 - 11 -  
4.3  Effects of CETP on LDL subclass remodeling 
  An association of large LDL and low CETP activity with Taq1B polymorphism was 
found in men, but not in women in the genetic epidemiological survey of Framingham 
Study [Ordovas et al. 2000].  In remodeling of apoB-containing lipoproteins, addition 
of CE increases lipoprotein size and deletion of PL and FC decrease its size, resulting in 
2 homogenous LDL subclasses [Musliner et al. 1991]. Complete CETP deficiency 
produced unique characteristics of broad LDL band with (at least 5) distinct IDL-LDL 
subclasses on a native polyacrylamide gel [Sakai et al. 1991], but partial CETP 
deficiency increased LDL size. 
4.4  Effects of CETP on macrophage-specific RCT in mice and hamsters 
 In radioactive cholesterol-labeled macrophage methodology, Rader et al have shown  
direct RCT from peripheral macrophages to liver, bile and feces. In LDLR-KO mice, 
CETP cDNA adeno-associated virus mediated transfection promotes cholesterol 
transport to the liver, but not to bile and feces. In contrast, in SRBI-KO mice, CETP 
cDNA transfection increased cholesterol loss in the feces, indicating induction of overall 
RCT via active LDL-R activity despite diminished selective uptake of HDL-CE (or FC) 
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in the liver [Tanigawa et al. 2007]. The former model is similar to the setting of 
familial hypercholesterolemia (FH) or down-regulated LDL receptor activity by a 
saturated-fat diet, while the latter model of decreased SR-BI activity reflects conditions 
found in the hormone replacement therapy [Oliveira et al. 2003]. Thus, 
macrophage-specific RCT is dependent on CETP activity and LDL receptor in the liver, 
and the efficacy of fecal sterol excretion is not always correlated with atherogenicity of 
plasma lipoproteins, indicating that measuring fecal sterol is not useful as a CHD 
biomarker. 
   In hamsters, torcetrapib, a CETP inhibitor, elevated HDL-C levels and the amounts 
of cholesterol and bile acids secreted in feces, indicating an overall increased RCT 
[Tchoua et al. 2008]. Such a difference may be explained (at least in part) by the 
presence of natural CETP activity and the inducible CYP7A gene found in hamsters 
[Zhang AH et al. 2004]. 
4.5  Effects on cholesterol efflux and preβHDL formation 
 Subjects with complete CETP deficiency have more preβHDL despite less 
remodeling from large HDL to small subclasses via CETP [Asztalos et al. 2004]. Thus, 
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increased preβHDL levels are caused by impaired maturation to large HDL due to 
decreased endogenous LCAT activity [Oliveira et al. 1997] or increased lipolysis of 
TG-rich lipoproteins [Miyazaki et al. 2009]. Since LCAT mass and exogenous LCAT 
activity remain at normal levels, impaired LCAT activity is explained either by 1) 
end-product inhibition namely excess CE in large HDL or by 2) altered phospholipid 
composition, such as sphingomyelin (SM) levels, in HDL. Plasma cholesterol 
esterification rate was decreased in CETP deficiency, which is compatible with altered 
lipid composition found in homozygous CETP deficiency; i.e. high CE/TG ratio and 
low PL/FC ratio [Koizumi et al. 1991]. Since CER is inversely associated with SM/PC 
ratio in HDL, SM itself may be an unsuspected link between low cholesterol 
esterification rate and low CETP activity [Noguchi and Inazu, unpublished data]. 
However, SM-rich lipoproteins are not always pro-atherogenic, because SM avidly 
binds cholesterol, and HDL with increased SM levels may be good acceptors for 
cholesterol efflux from atherosclerotic plaques [Fournier et al. 1997]. Increased HDL 
levels found in CETP deficiency had no beneficial effect on the ABCA1-mediated 
cholesterol efflux but did enhance SR-BI-mediated efflux [Miwa et al. 2009]. 
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4.6 Lipoprotein metabolism in CETP deficiency from a kinetic study 
Initially, Ikewaki et al reported delayed catabolism of apoA-I and apoA-II in human 
subjects with CETP deficiency [Ikewaki et al. 1993]. Also, they reported increased 
catabolic rate of LDL-apoB in addition to decreased production rate of VLDL-apoB 
[Ikewaki et al. 1995]. In a CETP-deficient dog, Ouguerram et al reported that VLDL 
and LDL CE metabolism was coupled to apoB catabolism without enrichment of CE 
during VLDL-LDL conversion and that 60% of HDL CE turnover was mediated by a 
selective uptake pathway [Bailhache et al. 2004; Ouguerram et al. 2004]. As 
compared to other CETP-deficient animals, dogs have higher selective uptake of 
HDL-CE (60% vs. 25-30% in rat and mice). The cholesterol esterification rate of dog 
plasma is 160 nmol/ml/h, which is between the rates in human (30-80 nmol/ml/h) and in 
rats (300 nmol/ml/h). Thus, dogs may have an efficient RCT due to high activities of 
SR-BI and LCAT in addition to CETP deficiency. 
 
5. Role of CETP in apoE-rich HDL formation 
 
5.1 structure of apoE-rich HDL 
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Plasma HDL is classifief as HDL1 (density 1.08-1.09 g/ml), HDL2 (1.09-1.15), and 
HDL3 (1.15-1.18). HDL1 is apoE-rich with a diameter of 13-19nm And increased 
LCAT activity compared with HDL2 and HDL3 [Schmitz and Assmann, 1982]. HDL1 
is also identified in cholesterol-fed CETP-deficient animals such as canine and swine.  
5.2 Function of apoE-rich HDL 
In cultured smooth muscle cells, cholesterol from HDLc, lipoproteins with apoE only 
(density 1.006-1.02), present in cholesterol-fed canine plasma, was efficiently delivered 
to the cells as well as LDL [Mahley et al. 1977]. ApoE-rich HDL appears in various 
situations such as genetic dyslipidemia, but its characteristics may not be uniform. In 
cholesterol-fed canine, plasma cholesterol increases, HDL loses apoA-I but it gains 
apoE. HDLc appears (as well as occurrence of LDL and β-migrating VLDL) when 
cholesterol exceeds 700 mg/dl. Thus, HDL1 and HDLc appeared to suppress 
apoB-containing lipoprotein formation in the liver, such as LDL and β-VLDL. Thus, 
one would predict that these lipoproteins would inhibit atherogenesis in canine models. 
  ApoE-rich HDL have dual roles in atherogenicity. ApoE can serve as an LRP ligand, 
and therefore canine HDLc inhibits clearance of chylomicrons [Hussain et al. 1995]. 
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However, post-prandial lipemia is diminished in homo- and heterozygous CETP 
deficiency [Inazu et al. 2008]. VLDL lipolysis and hepatic uptake of CM/VLDL 
remnant appear to be increased probably due to apoE transfer from HDL to CM/VLDL 
during post-prandial periods [Krimbou et al. 2003]. 
  ApoE-rich HDL reduces LPL-mediated retention of LDL by subendothelial matrix, 
and therefore could be anti-atherogenic role in artery walls. Also, apoE-rich lipoproteins 
protect cells from apoptosis via the LRP signaling pathway [Hayashi et al. 2007]. 
  In SB-B1 knockout mice, LCAT activity was impaired and oxidative stress was 
increased in large HDL [Lee, 2007; Van Eck 2007]. Remnant-like particle cholesterol 
(RLP-C) levels reflect cholesterol levels (10-15 mg/dl) of large apoE-rich HDL 
(probably apoE only particles) in homozygous CETP deficiency [Inazu et al. 2008]. 
The apoE-rich HDL contains apoA-IV as well as apoA-I [Bisgaier et al. 1991], but the 
RLP fraction of homozygous CETP deficiency had large amount of apoE with a trace of 
apoA-I and apoA-IV. 
6. Molecular genetics and the ethnic difference in the frequency of human CETP 
deficiency 
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Plasma CETP deficiency was originally reported in Japanese siblings with 
hyperalphalipoproteinemia (HALP) [Koizumi et al. 1985]. The first mutation was 
found in a splice donor site mutation in intron 14 (intron 14 G[+1]-to-A.), resulting in 
non-tranlsation of exon 14 and production of a stop codon in the 4th codon encoded by 
exon 15.  These changes resulted in decreased mRNA levels to one-third of controls 
and a truncated protein that appeared to be rapidly degraded  [Brown et al. 1989; 
Gotoda et al. 1997].  
 So far 20 different mutations have been found both in Asian and Caucasian 
populations, but predominantly in Asians [Nagano et al. 2004; Thompson et al. 2009]. 
Two mutations were found in both ethnic groups (R268X and intron 14 G(+1)-to-A), 
suggesting multiple origins of these mutations (de novo mutations) [Ai et al. 2009]. 
Both mutations indeed have CpG sequences as mutational hot spots for deamination of 
the cytosine. Although many mutations are nonsense or splicing mutations, 4 missense 
mutations are reported to be associated with decreased CETP activity (L151P, L261R, 
R282C, and D442G). Only one promoter mutation was reported at –69G>A.  
  Large differences in the frequency of CETP deficiency in various populations appear 
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to be related to the frequency of two variants. The intron 14 G(+1)-to-A mutation is the 
Japanese-type mutation with the higher gene frequency (0.8% in the general population 
of Japan). Homozygotes of this mutation were reported in >50 cases reflecting relatively 
higher frequency of consanguinity in Japan in the past generations.  
 
7. Clinical chemistry of LDL-cholesterol and HDL-cholesterol in CETP deficiency 
Homozygotic mutations result in complete CETP deficiency with a phenotype of very 
high HDL-C levels and relatively low LDL-C levels (mean levels of 164 mg/dl and 77 
mg/dl, respectively) [Inazu et al. 1990]. Heterozygotes have a moderate increase in 
HDL-C (mean 66 mg/dl) and a decrease in plasma CETP levels (mean 1.4 mg/L) as 
compared to unaffected controls (53 mg/dl and 2.3 mg/L). Asp 442 Gly (D442G) is 
another highly prevalent mutation in Japan (3.4% in the general population of Japan) as 
well as in other Asian populations (1.7-5.9%), although it is only partially defective in 
CETP activity [Inazu et al. 1994]. The compound heterozygotes of intron 14 
G(+1)-to-A and D442G produce a less severe phenotype of CETP deficiency (n=9, 
CETP 0.9 +-0.3 [SD] mg/L, HDL-C 130+-24 mg/dL) as compared to mean levels of 
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plasma CETP were 1.8+-0.6 mg/L (SD) in Japanese men and 2.0 +-0.5 in women 
[Kiyohara et al. 1998]. 
7.1 LDL-C measurement 
The Friedewald formula, LDL-C = TC – HDL-C – (TG/5), is used for estimation of 
LDL-C, but accurate measurement for HDL-C is required. For the precipitation method 
for HDL-C, the Cholesterol Reference Method Laboratory Network (CRMLN) using a 
heparin, Mn2+ supernatant cholesterol of plasma d>1.006 [Centers for Disease Control 
and Prevention (CDC)] is better than the Designed Comparison Method (DCM) using 
dextran-sulfate, Mg2+ supernatant cholesterol levels, since the latter precipitates 
apoE-rich HDL in addition to apoB-containing lipoproteins, but the former does not. 
  Even if accurate measurement of HDL-C is accomplished, cholesterol levels in 
VLDL are relatively decreased in CETP deficiency [Koizumi et al. 1991].  Therefore, 
the Friedewald formula would underestimate LDL-C. However, since the density 
between 1.019 and 1.063 includes apoE-rich large HDL such as HDL1, the LDL-C 
separated by ultracentrifugation would overestimate LDL-C. Suitability for the LDL-C 
assays has not been reported in homozygous CETP deficiency. 
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7.2 ApoE-rich HDL-C determination 
As a more suitable precipitation method for HDL-C in CETP deficiency, Chiba et al 
reported that 13% polyethylene glycol allows recovery of total HDL in the supernatant 
[Chiba et al. 1997]. In that study, patients with complete CETP deficiency had a mean 
HDL-C level of 121 mg/dl detected by a commercial polyanionic reagent (dextran 
sulfate, sodium phosphotungstate, Mg2+), but 176 mg/dl of total HDL-C using 
supernatants produced by the PEG method.  The difference (~55 mg/dl) may indicate 
cholesterol levels in apoE-rich HDL. 
8. Epidemiology of increased HDL cholesterol levels and CETP deficiency 
HDL-cholesterol could be excreted from bile as consequence of reverse cholesterol 
transport (RCT) involving HDL maturation from preβHDL to apoE-rich HDL. 
However, CETP would bypass the cholesterol flow from HDL to VLDL-LDL without 
involving the liver. Thus, CETP-mediated CE transfer would increase indirect 
cholesterol transport to the liver via VLDL-IDL-LDL through LDL receptor or remnant 
receptors pathways. In addition, HDL-cholesterol is directly transported to the liver by 
selective uptake of HDL-CE or FC via hepatic lipase and/ or SR-BI pathway.  
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  Thus, the role of the CETP pathway appears to be anti-atherogenic when LDL levels 
are low and TRL clearance is rapid on a low-fat diet. However, the Western-type 
saturated-fat diet would suppress LDL receptor expression, and the flow of 
HDL-derived cholesterol back to the liver would be diminished via LDL pathway. 
Indeed, subjects with high CETP activity may manifest lower coronary risk in the 
presence of low plasma TG levels [Borggreve et al. 2007].  The role of CETP in 
LDL-receptor deficiency (familial hypercholesterolemia) is controversial, since double 
heterozygotes with FH and CETP deficiency are not protected from CHD [Haraki et al. 
1997]. It remains to be discussed whether slightly increased HDL-C (60 mg/dl vs. 46 
mg/dl) is not sufficient to prevent CHD or whether lower CETP is disadvantageous in 
FH. 
8.1 Epidemiology of HDL cholesterol 
In earlier studies by Gofman et al [Gofman et al. 1966], levels of HDL2 and HDL3 
were significantly decreased in patients with CHD, but HDL1 levels were not changed. 
In heparin-Sepharose chromatography, HDL-apoE levels were significantly decreased 
in survivors with myocardial infarction [Wilson et al. 1993]. In a proteomic study of 
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HDL proteins, apoE levels in the HDL3 fraction were increased in patients with CHD 
[Vaiser et al. 2007], but unfortunately no data were available on HDL2 or VLDL. 
   Inconsistency of anti-atherogenicity of HDL might be explained by how much large 
HDL or apoE-rich HDL are increased, as these particles are believed to have less 
anti-atherogenic effects compared to small HDL. When apoA-I and apoB are kept 
constant, HDL-C and HDL particle size may confer risk at very high values [van der 
Steeg et al. 2008]. On the contrary, apoA-I is a negative risk factor even when corrected 
for HDL-C and apoB, suggesting that HDL number assessed by apoA-I concentration is 
statistically more important than HDL size for anti-atherogenicity effects. The debate 
over whether HDL size or its components are more important for atherogenesis should 
be answered by measuring specific HDL-related lipid component levels such as 
sphingomyelin, sphingosine-1-phosphate, and dolichol in HDL of various dyslipidemia 
[Kontush et al. 2007]. 
8.2 The role of confounding factors in increased HDL state (Table 2) 
In many reports, a high HDL-C state is a negative risk factor of CHD and stroke [Kurth 
et al. 2007]. Since low HDL-C is inversely associated with increased TG levels, low 
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HDL appeared to be a marker for disturbed TG metabolism [Schaefer et al. 1994]. 
However, some reports suggest a U-shape relationship with HDL-C and vascular events 
[Chien et al. 2002].  Such a relationship may be associated with some confounding 
factors associated with increased HDL-C levels: alcohol, estrogen and exercise 
[Williams 1996]. There are reports of adverse interaction between alcohol and 
hypertension on stroke [Leppala et al. 1999]. Others have suggested an interaction 
between increased levels of TG and HDL-C on CHD [Jeppesen et al. 1998]. A large 
genetic epidemiological survey is warranted to find associations between CETP or 
hepatic lipase polymorphisms and CHD events, especially by interacting with 
environmental factors such as alcohol consumption and hormone replacement therapy. 
Since lower activities of hepatic lipase and SR-BI and higher CETP are characteristics 
of premenopausal women, consideration of gender difference is necessary in unraveling 
the interactions between HDL and CHD [Jansen et al. 2002]. 
 8.3 The role of CETP mutations and polymorphisms on CHD risk    
A meta-analysis of studies including CETP gene SNPs of TaqIB2, -629C>A and Ile 405 
Val (I405V) showed that the genotypes with low CETP may have anti-atherogenic 
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effects [Thompson et al. 2008]. Our data suggested that –1337C>T is responsible for 
the anti-atherogenicity of the well-investigated TaqIB2 allele in the Japanese population 
[Lu et al. 2003; Takata et al. 2006]. Thus, anti-atherogenicity of lower CETP levels 
was also suggested in heterozygous CETP deficiency [Curb et al. 2004]. 
  CHD prevalence appears to be low in homozygous CETP deficiency, which is 
compatible with findings of the Kochi Study of cross-sectional survey of disease 
prevalence stratified by increased HDL-cholesterol levels >80 mg/dl and >100 mg/dl 
[Moriyama et al. 1998]. Three hundred subjects with HDL-C > 100mg/dl were found 
in that paper, but no case with CHD was found. Indeed, high HDL-cholesterol and 
intron 14 G(+1)>A variant may increase the odds for healthy aging in the Honolulu 
Heart Program Study [Koropatnick et al. 2008]. Consistently, recent case reports of 
Caucasian CETP deficiency have shown the rarity of atherosclerotic disease even 
though Western diets were consumed [Teh et al. 1998; Rhyne et al. 2006]. However, 
some investigators believe pro-atherogenicity in some cases with homozygous CETP 
deficiency [Nagano et al. 2005]. In contrast, there is no define CHD, but 2 cases with 
cerebrovascular disease were found in our cohort of homozygous CETP deficiency 
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(n=53)  
8.4 Malignancy association 
In earlier studies, Keys suggested a possible association between increased HDL-C 
levels and malignancy incidence [Keys 1983]. The failure of torcetrapib is a reminder of 
such a possible association. This issue should be assessed in studies using other CETP 
inhibitors. 
9. Development of CETP inhibitor 
Three compounds are currently in clinical trials, torcetrapib (CP-529414), anacetrapib 
(MK-859) and dalcetrapib (JTT-705/ Roche R1658). Phase III of torcetrapib was 
terminated on December, 2006 due to unexpected excess of mortality in the torcetrapib 
arm. The early termination was partially explained by hypertension due to aldosterone 
excess. However, the role of CETP inhibition on the increased mortality was not clearly 
shown, but it may be rather associated with infection or malignancy than CHD [Barter 
et al. 2007]. 
  The vascular endpoints of carotid atherosclerosis and coronary atheroma volume 
assessed by intravascular ultrasound showed no benefit from torcetrapib over a 
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background of atorvastatin treatment, despite increased levels of HDL and further 
decreased levels of LDL and TG [Nissen et al. 2007; Kastelein et al. 2007]. 
  HDL-cholesterol might be excreted from bile as consequence of reverse cholesterol 
transport (RCT) involving HDL maturation from preβHDL to apoE-rich HDL. Using a  
CETP inhibitor, CE uptake of liver was not decreased in rabbits, but fecal sterol 
excretion was not increased in patients taking torcetrapib, indicating that overall RCT 
was not significantly induced [Brousseau et al. 2005; Kee et al. 2006; Catalano et al. 
2009]. Torcetrapib did increase overall RCT assessed by cholesterol and bile acids in 
feces of hamsters [Tchoua et al. 2008]. Such a difference in the response to CETP 
inhibitor definitely needs to be clarified. 
9.1 Effects on small HDL subclasses 
Hyperalphalipoproteinemia (HALP ) caused by prednisone plus cyclosporine was 
ineffective in producing HDL acceptors for cholesterol efflux. The ABCA1-dependent 
efflux was maintained, but the non-ABCA1-dependent route appeared to be impaired 
[Sviridov et al, 2006]. 
  CETP inhibition may disturb apoA-I liberation from HDL in atherosclerotic lesions. 
 9/7/2017 Akihiro INAZU  
 - 27 -  
Therefore, ABCA1-mediated cholesterol efflux activity to small HDL or liberated 
apoA-I could be compromised. However, recent studies suggest that the ABCG1 
transporter may favorably induce cholesterol efflux from cells to large HDL 
[Yvan-Charvet et al, 2007]. Torcetrapib would increase this large HDL level, which is 
an active cholesterol acceptor for ABCG1 or SR-BI-mediated efflux, although the role 
of SR-BI-mediated cholesterol efflux remains controversial [Yvan-Charvet et al, 2008]. 
Although small HDL, such as HDL3 subclass, is known to protect LDL from oxidation 
[Davidson et al. 2009], HDL3 levels were not increased in genetic CETP deficiency, 
but they were moderately increased in patients with CETP inhibitors. 
9.2 Effects on apoB-containing lipoproteins 
  By inhibiting neutral lipid transfer among lipoproteins, CE transfer from HDL to 
VLDL in exchange with TG was diminished. Therefore, relatively CE-poor, TG-rich 
VLDLs were lipolysed to LDL and VLDL-IDL-LDL were rapidly removed from the 
circulation probably due to LDL-receptor upregulation [Millar et al. 2006]. In LDL 
subclasses, small-and-dense LDL levels were decreased but large LDL levels were 
increased in patients with torcetrapib [Brousseau et al, 2004], which is compatible with 
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a phenotype in low CETP subjects with a TaqIB2 polymorphism [Ordovas et al. 2000]. 
Plasma Lp(a) levels were decreased in CETP deficiency, and ~50% reduction of plasma 
Lp(a) levels was achieved by anacetrapib [Bloomfield et al. 2008]. 
  Large HDL contains multiple apoE molecules, but such lipoproteins could be 
efficiently removed from the circulation via increased LDL receptor expression. Thus, 
increased levels of apoE-rich HDL produced by a CETP inhibitor could be offset by 
combination therapy with a statin, which induces LDL receptor expression and 
increases hepatic uptake of apoE-rich HDL. Increased RCT was found when both CETP 
and LDL receptor are up-regulated in the liver. Thus, combination therapy with a CETP 
inhibitor and a statin would result in opposite responses in the RCT pathway, a finding 
that would be compatible with a proposed adverse pharmacogenetic interaction between 
a statin and a CETP inhibitor [Regieli et al. 2008]. 
10. Role of CETP in aging and longevity (Figure 2) 
CETP enhances HDL remodeling from large HDL to small subclasses including 
pre-HDL. However, CETP deficiency would decrease cholesterol esterification rate, 
thereby inhibiting maturation of preβHDL to α-migrating spherical HDL. Therefore, 
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in CETP deficiency, large-to small HDL remodeling is decreased and preβHDL 
catabolism is also decreased. The levels of preβHDL were increased in homozygous 
CETP deficiency, but those were decreased in the heterozygotes [Asztalos et al, 2004], 
indicating that maturation of the small HDL subclass is preserved in heterozygotes, but 
not in homozygotes. The difference is dependent on the magnitude of low CER and low 
ABCA1-mediated efflux activity. 
  Recent studies suggested PAF-AH (lipoprotein-associated phospholipase A2) 
inhibitors could inhibit sdLDL formation, thereby preventing atherosclerosis in animal 
model and human. Plasma paraoxonase activity was decreased in HALP with hepatic 
lipase deficiency [Kontush et al. 2004].  Thus, the anti-oxidant activity of HDL needs 
to be evaluated in patients treated with CETP inhibitors. 
10.1 Effects on aging and Alzheimer’s disease 
  A promising effect on longevity has been reported in Ashkenazi Jews, as increased 
homozygosity of I405V was found in offspring of individuals with exceptional 
longevity (mean age 98 yrs). These subjects had high HDL, low LDL and large LDL 
size, and low prevalence of hypertension and metabolic syndrome [Barzilai et al. 
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2003]. 
  A different CETP polymorphism (D442G) may have a protective effect against the 
development of Alzheimer’s disease (AD), especially in apoE4 carriers in the Chinese 
population [Chen et al. 2007]. But, the opposite relationship between another CETP 
polymorphism (I405V) and AD was found in the Dutch population [Arias-Vasquez et 
al. 2007]. Indeed, the CETP gene haplotype was associated with both markers of 
cholesterol synthesis and degradation in the cerebrospinal fluid and CETP may have 
neuronal repair effects through PL transfer activity. Data regarding possible AD 
associations between genes for CETP and apoE are conflicting, and need to be 
resolved.. 
10.2 Susceptibility to infectious disease 
As CETP belongs to the lipopolysaccharide binding protein (LBP) gene family, a role 
for CETP has been suggested in infection. Since LBP and lipoprotein may be associated 
with the detoxification of endotoxin, apoB-containing lipoprotein levels may reflect the 
efficacy of LBP function [Vreugdenhil et al. 2001].  Along with an increase of LBP, 
plasma cholesterol, PL, LDL-C, HDL-C decrease, whereas plasma TG, VLDL and 
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apoE-rich HDL tend to be increased after intravenous endotoxin [Hudgins et al. 2003; 
Li et al. 2008]. 
    In experimental endotoxemia, increased CRP levels are found with reciprocal 
decreases of LCAT and CETP activities [Levels et al. 2007]. CETP expression was 
suppressed by cytokines of TNFαand IL-1. PLTP deficiency led to a significant 
increase in LPS-induced mortality in mice [Gautier et al. 2008]. Thus, we need to 
consider possible disadvantages of CETP deficiency in terms of endotoxemia, because 
CETP would enhance the LPS binding to HDL /LDL. The liver uptake of LPS was 
greater in CETP-transgenic mice than controls, suggesting accelerated clearance of LPS 
from circulation [Cazita et al. 2008]. 
  On the other hand, large HDL found in CETP deficiency might be protective against 
Schistosoma japonicum [Okamura-Noji et al. 2001].  
11. Role of CETP in dyslipidemia associated with diabetes and metabolic syndrome 
(Table 2) 
  In hyperlipidemic patients, increased production of VLDL and/or decreased 
catabolism of LDL are major risk factors in addition to low HDL-C. Since decreased 
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production rate of VLDL appears to be associated with decreased CETP activity in 
patients with metabolic syndrome treated by fenofibrate [Watts et al. 2006]. A CETP 
inhibitor may be especially useful for combined hyperlipidemia of high VLDL and low 
HDL levels. LDL catabolic rate is increased in CETP inhibitor, but effects on VLDL 
production rate have been less established.  
  Plasma CETP levels are increased in metabolic syndrome [Sandhofer et al. 2006]. 
Plasma PLTP levels are increased, but the increase in CETP is somewhat controversial 
in diabetes [Dallinga-Thie et al. 2007]. Plasma CETP activity was positively related 
with CETP mass, and negatively to HbA1c [Dullaart et al. 2004]. In diabetes, 
decreased sterol regulatory element binding protein (SREBP) expression may lead to 
lower CETP expression in the liver [MacLean et al. 2005]. Phosphoinositide 3-kinase 
activity is decreased in diabetes, and liver SR-BI expression is decreased [Shetty et al. 
2006]. Since increased CETP activity may be beneficial in diabetes as shown in a db/db 
mouse study [MacLean et al. 2003], such a complex relationship should be examined 
in human diabetes. 
   In the Copenhagen City Heart Study, elevated HDL-C caused by a I405V 
 9/7/2017 Akihiro INAZU  
 - 33 -  
polymorphism is a risk for CHD in women without hormone replacement therapy but 
not in men [Agerholm-Larsen et al. 2000]. Atherogenicity of CETP may be related to 
SR-BI expression in terms of RCT to bile cholesterol excretion. Hepatic SR-BI is 
induced by a diet rich in polyunsaturated fat, but suppressed by cholesterol, vitamin E 
and estradiol. As shown in knock-out mice, SR-BI deficiency is associated with 
increased HDL levels but it is pro-atherogenic [Trigatti et al. 1999].  
   Thus, specific attention may be required for diabetic and female patients when a 
CETP inhibitor is considered, because reduced SR-BI expression is assumed in those 
conditions. Also, usefulness of combination therapy with a statin (HMG-CoA reductase 
inhibitor) and a CETP inhibitor needs to be validated experimentally. 
12. Perspectives 
More studies are needed for development of HDL intervention through inhibiting 
plasma CETP activity. Especially, it is important to assess how to suppress plasma 
CETP activity. Antisense CETP therapy is of greater interest than chemical compounds 
because the antisense therapy would decrease plasma CETP mass.  
  In protection of neuronal disease, more study of cerebrospinal fluid lipoprotein is 
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needed in terms of compositions of apoE and lipid transfer proteins and pharmaceutical 
changes in those lipoproteins. In addition to CE/TG transfer, CETP may transfer 
estrogen-ester and retinyl-ester but not vitamin E. Anti-oxidative local effects of CETP 
may be more important under oxidative stress or combined metabolic conditions of 
PTLP deficiency, which is defective in vitamin E transport. Thus, the role of CETP in 
terms of lipoprotein oxidation needs to be clarified in various setting of concurrent 
hyperlipoproteinemia or hormonal exposure such as estrogen. LPS is associated not 
only with endotoxemia, but also with vascular oxidative stress and inflammation. 
Therefore, role of CETP in LPS metabolism needs to be clarified in CETP deficiency 
and patients treated with CETP inhibitors. 
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Table 1. Plasma endogenous and exogenous LCAT activity and exogenous CETP 
activity in young women (n=38) 
 
HDL enzyme/ protein Method Mean (SD) Range 
LCAT, endogenous Self substrate method 
Nagasaki and Akanuma (1977) 
 
110 (20) 80-180 
LCAT, exogenous Common substrate method 
Manabe et al (1987) 
 
590 (110) 330-900 
CETP NBD-cholesteryl ester transfer 
activity between proteoliposome 
to VLDL 
210 (30) 150-290 
All units are nmol/ml/h. 
Endogenous LCAT activity of cholesterol esterification rate is only ~20% of exogenous 
LCAT activity, the latter is correlated with plasma LCAT mass. Endogenous LCAT 
activity is only ~50% of plasma CETP activity, therefore HDL-FC/CE ratio could be 
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Table 2. Gender difference in HDL-associated biological activities 
 CETP Hepatic lipase SR-BI 
Men Low High High 
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Figure legends 
Figure 1. Schema for HDL metabolism 
Plasma cholesteryl ester transfer protein (CETP) facilitates to exchange neutral lipids of 
CE and TG between chylomicron (CM)/ VLDL and HDL2. HDL-TG is provided by 
CETP, and it is subsequently hydrolyzed by hepatic lipase (HL). The synthetic rate of 
preβ1HDL is positively correlated with lipoprotein lipase (LPL)-mediated lipolysis or 
PLTP-mediated PL/FC transfer and increased cholesterol efflux by ABCA1 transporter. 
On the other hand, catabolic rate of preβ1HDL is correlated with cholesterol 
esterification rate by lecithin: cholesterol acyltransferase (LCAT). Thus, preβ1 HDL 
levels are determined by activities of LPL, PLTP, ABCA1, and LCAT. 
 
Figure 2. Differential metabolic fate of HDL in heterozygous and homozygous 
CETP deficiency 
(A) In heterozygotes, both CM/VLDL lipolysis and cellular ABCA1-mediated FC/PL 
efflux are maintained. Also, LCAT reaction is relatively preserved. Thus, decrease in pre
β1 HDL indicates that HDL maturation is not disturbed. 
(B) In homozygotes, both CM/VLDL lipolysis is enhanced and the cellular efflux are 
diminished. Also, LCAT reaction is severely suppressed. Thus, preβ1 HDL is 
accumulated in plasma. 
 
Table 2R.  Gender difference in HDL-associated biological activities 
 
 Transfer proteins, enzyme, receptor Lipoprotein phenotype 
 CETP PLTP Hepatic 
lipase 
SR-BI HDL2b preβ-HDL 
Men low high high high low high 
Women* high low low low high low 
*premenopausal state 
LPL activity is not different between men and women. 
 






























Figure 2 (A) 












Figure 2 (B) 
Notes added in the proof 
 
13. Low CETP status, genetic or environmental? 
 
Recent publications suggested that low CETP mass is associated with 
lipid-lowering drugs, history of myocardial infarction, diabetes, smoking, and 
inflammation with elevations of CRP and IL-6 (Ritsh et al, 2010). Indeed, CETP 
expression was decreased in leukocytes and macrophages in acute coronary 
syndrome (Ye et al. 2008), suggesting down-regulation of CETP expression 
during acute inflammation. 
 In addition, Vasan et al have shown that low CETP activity was associated with 
greater cardiovascular risk in a prospective study of the Framingham Heart 
Study (Vasan et al. 2009).  Thus, cause of low CETP activity needs to be 
clarified to insight conflicting data between CETP activity and cardiovascular risk. 
Thus, both genetic and environmental factors need to be assessed in a 
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